ARDS & mechanical ventilation

11 trials
  • 2022RECOVERY-RSOxygenation strategyIn 1,273 patients with COVID-19 acute hypoxaemic failure, CPAP reduced intubation or death versus conventional oxygen, while HFNO did not.
  • 2019ROSENeuromuscular blockadeIn 1,006 patients with moderate–severe ARDS on high PEEP, early cisatracurium did not reduce 90-day mortality versus light sedation.
  • 2018EOLIAECMOIn 249 patients with very severe ARDS, early VV-ECMO did not significantly reduce 60-day mortality versus conventional ventilation with rescue ECMO.
  • 2015FLORALIOxygenation strategyIn 310 patients with acute non-hypercapnic hypoxaemic respiratory failure, high-flow nasal oxygen improved 90-day mortality compared with standard oxygen or NIV.
  • 2013PROSEVAProne positioningIn 466 patients with severe ARDS (P/F <150), early prone positioning ≥16 h/day reduced 28-day mortality compared with supine ventilation.
  • 2013OSCILLATEHFOVIn 548 patients with moderate–severe ARDS, high-frequency oscillatory ventilation increased in-hospital mortality compared with low-tidal-volume ventilation.
  • 2010ACURASYSNeuromuscular blockadeIn 340 patients with severe ARDS within 48 hours, 48-hour cisatracurium infusion reduced 90-day mortality compared with placebo.
  • 2009CESARECMOIn 180 patients with severe respiratory failure, transfer to an ECMO centre improved 6-month survival without severe disability versus continued conventional care.
  • 2006FACTTFluid strategyIn 1,000 patients with ARDS, a conservative fluid strategy did not change 60-day mortality versus a liberal strategy, but increased ventilator-free days.
  • 2004ALVEOLIPEEP strategyIn 549 patients with ARDS, a higher PEEP strategy did not reduce in-hospital mortality compared with a lower PEEP strategy.
  • 2000ARMALung-protective ventilationIn 861 patients with ARDS, 6 mL/kg tidal-volume ventilation reduced in-hospital mortality compared with 12 mL/kg.